ATE261313T1 - Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten - Google Patents

Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Info

Publication number
ATE261313T1
ATE261313T1 AT96932269T AT96932269T ATE261313T1 AT E261313 T1 ATE261313 T1 AT E261313T1 AT 96932269 T AT96932269 T AT 96932269T AT 96932269 T AT96932269 T AT 96932269T AT E261313 T1 ATE261313 T1 AT E261313T1
Authority
AT
Austria
Prior art keywords
ultrafiltration
producing
proteosomeamphiphilic
diafiltration
vaccine
Prior art date
Application number
AT96932269T
Other languages
English (en)
Inventor
George H Lowell
Wendell D Zollinger
James F Wood
Original Assignee
Us Army Medical Res Materiel C
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE261313(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army Medical Res Materiel C, Id Biomedical Corp Quebec filed Critical Us Army Medical Res Materiel C
Application granted granted Critical
Publication of ATE261313T1 publication Critical patent/ATE261313T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT96932269T 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten ATE261313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (1)

Publication Number Publication Date
ATE261313T1 true ATE261313T1 (de) 2004-03-15

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96932269T ATE261313T1 (de) 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Country Status (20)

Country Link
US (1) US6476201B1 (de)
EP (1) EP0854729B2 (de)
JP (2) JP4033489B2 (de)
KR (1) KR19990045763A (de)
CN (1) CN1211192A (de)
AT (1) ATE261313T1 (de)
BR (1) BR9610484A (de)
CA (1) CA2232410C (de)
CZ (1) CZ298460B6 (de)
DE (1) DE69631835T3 (de)
DK (1) DK0854729T3 (de)
EA (1) EA199800208A1 (de)
ES (1) ES2217325T5 (de)
HU (1) HUP9901577A3 (de)
IL (1) IL123720A (de)
MX (1) MX9802128A (de)
NO (1) NO320074B1 (de)
PL (1) PL325604A1 (de)
PT (1) PT854729E (de)
WO (1) WO1997010844A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1228217B1 (de) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Konservierte antigene aus neisseria
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
EP1721618A3 (de) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteasom-influenzavirus-impfstoffzusammensetzung
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
EP2255826B1 (de) * 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisseria impfstoffzusammensetzungen die eine kombination von antigenen enthalten
PT2353608T (pt) * 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
WO2005027964A1 (en) * 2003-09-15 2005-03-31 Id Biomedical Corporation Of Quebec Measles subunit vaccine
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
SG186686A1 (en) 2004-06-25 2013-01-30 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
EP1778283A2 (de) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
TWI565713B (zh) 2006-08-07 2017-01-11 哈佛大學校長及研究員協會 蛋白基質疫苗以及該疫苗的製造與使用方法
US20100288029A1 (en) * 2006-08-30 2010-11-18 Ge Healthcar Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
JP5723768B2 (ja) * 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
AU2010292195A1 (en) * 2009-09-09 2012-03-15 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
AU2015321698B2 (en) * 2014-09-24 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
CA2232410C (en) 2003-06-17
PL325604A1 (en) 1998-08-03
MX9802128A (es) 1998-11-29
BR9610484A (pt) 2001-09-11
US6476201B1 (en) 2002-11-05
EP0854729B1 (de) 2004-03-10
NO981189L (no) 1998-05-14
NO320074B1 (no) 2005-10-17
DE69631835T3 (de) 2009-03-05
IL123720A (en) 2002-02-10
CZ81998A3 (cs) 1998-10-14
CN1211192A (zh) 1999-03-17
EA199800208A1 (ru) 1998-10-29
NO981189D0 (no) 1998-03-17
PT854729E (pt) 2004-08-31
HUP9901577A2 (hu) 1999-08-30
JP2004099619A (ja) 2004-04-02
EP0854729A1 (de) 1998-07-29
EP0854729B2 (de) 2008-10-22
CA2232410A1 (en) 1997-03-27
JP2000507913A (ja) 2000-06-27
ES2217325T5 (es) 2009-04-01
DE69631835T2 (de) 2005-02-10
DK0854729T3 (da) 2004-07-12
KR19990045763A (ko) 1999-06-25
JP4033489B2 (ja) 2008-01-16
WO1997010844A1 (en) 1997-03-27
CZ298460B6 (cs) 2007-10-10
ES2217325T3 (es) 2004-11-01
EP0854729A4 (de) 2000-02-02
HUP9901577A3 (en) 2000-03-28
DE69631835D1 (de) 2004-04-15
US20020164357A1 (en) 2002-11-07
IL123720A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
ATE261313T1 (de) Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
EP1297844A3 (de) Meningokokkus Multikomponentimpfstoff
GR3033469T3 (en) Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci.
HU185404B (en) Process for preparing pertussis toxoide
SE9003278L (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
Amend et al. Some factors affecting the potency of Yersinia ruckeri bacterins
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
DE59107901D1 (de) Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren
ES2560452T3 (es) Vacuna de IPV-DPT
JP2002537352A (ja) ナイセリアワクチン組成物および方法
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
PT90310B (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
ATE218369T1 (de) Verfahren zur herstellung von immunoaktiven mittel und impfstoffe
EP0082072B1 (de) Verfahren zur Herstellung eines biochemischen Vakzins gegen Salmonellenfieber
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
DE69804850D1 (de) Verfahren zur herstellung eines kappa-casein-glykomakropeptides oder eines abkoemmlings davon
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
RU2148412C1 (ru) Способ получения протективного коклюшного антигена
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
ATE266676T1 (de) Verwendung von aviären, vitellinen, gegen hiv- antigene gerichteten antikörpern zur herstellung pharmazeutischer zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854729

Country of ref document: EP

REN Ceased due to non-payment of the annual fee